TNBC - Triple-Negative Breast Cancer
Showing 1 - 25 of 35
TNBC - Triple-Negative Breast Cancer Trial in Wuhan (Utidelone, Tirelizumab, Bevacizumab)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Utidelone
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 5, 2023
TNBC - Triple-Negative Breast Cancer Trial in Brussels (Ga-PSMA PET/CT)
Recruiting
- TNBC - Triple-Negative Breast Cancer
- Ga-PSMA PET/CT
-
Brussels, BelgiumInstitut Jules Bordet
Sep 26, 2023
TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- Camrelizumab Plus Chemotherapy and Famitinib
- Camrelizumab Plus Chemotherapy
- (no location specified)
Aug 17, 2023
TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- Alkaline Glucosodiene Molecules
- (no location specified)
Jul 14, 2023
TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- A1:SG with SHR3680
- +7 more
- (no location specified)
Jun 23, 2023
Immunotherapy-related CRP Kinetics in Early and Metastatic
Recruiting
- TNBC - Triple-Negative Breast Cancer
-
Tuebingen, GermanyDepartment of Women's Health
Jun 13, 2023
TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- (no location specified)
May 8, 2023
TNBC - Triple-Negative Breast Cancer Trial in Nanjing (Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide)
Recruiting
- TNBC - Triple-Negative Breast Cancer
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 27, 2023
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer, Head Neck Cancer Trial (CA9hu-1)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma Metastatic
- +4 more
- (no location specified)
Jan 13, 2023
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, NSCLC, Squamous or Non-squamous Trial in Denver,
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +8 more
- XmAb®808
- Keytruda® (pembrolizumab)
-
Denver, Colorado
- +2 more
Jan 19, 2023
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)
Recruiting
- HER2-negative Breast Cancer
- +3 more
-
Houston, TexasHouston Methodist Neal Cancer Center
Jan 12, 2023
Breast Cancer BRCA1 Carriers: a Pilot Study
Withdrawn
- BRCA1 Mutation
- +2 more
- Mifepristone 200 MG
- Prophylactic mastectomy
-
Carmel, Indiana
- +1 more
Dec 13, 2022
Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG
Recruiting
- Breast Neoplasms
- +10 more
- Standard Therapy
- +32 more
-
Birmingham, Alabama
- +35 more
Nov 17, 2022
TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial in Worldwide (Trilaciclib, Placebo, Gemcitabine)
Active, not recruiting
- TNBC - Triple-Negative Breast Cancer
- Breast Cancer
- Trilaciclib
- +3 more
-
Birmingham, Alabama
- +111 more
Oct 25, 2022
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)
Completed
- Triple Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
-
Birmingham, Alabama
- +24 more
Sep 19, 2022
Immune Environment in Response to Therapy in Breast Cancer
Recruiting
- Breast Cancer
- +3 more
- Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
-
Philadelphia, PennsylvaniaAbramson Cancer Center
Sep 15, 2022
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
Recruiting
- Breast Cancer
- +2 more
-
Wuhan, Hubei, ChinaTongjiHospital
Sep 12, 2022
TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial (Pembrolizumab, Radiation Therapy, Axatilimab)
Not yet recruiting
- TNBC - Triple-Negative Breast Cancer
- Breast Cancer
- Pembrolizumab
- +2 more
- (no location specified)
Aug 4, 2022
Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial (Toripalimab, Epirubicin, High Intensity Focused Ultrasoun)
Not yet recruiting
- Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Toripalimab
- +5 more
- (no location specified)
Aug 5, 2022
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in United States (Sterotactic Body
Active, not recruiting
- TNBC - Triple-Negative Breast Cancer
- +6 more
- Sterotactic Body Radiotherapy/SBRT
- Standard of care
-
Basking Ridge, New Jersey
- +8 more
Jul 26, 2022
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant Trial in Bethesda, Nashville (TC-510, Fludarabine,
Recruiting
- Mesothelioma
- +14 more
- TC-510
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Jul 14, 2022